Fortschr Neurol Psychiatr 2011; 79(12): 733-743
DOI: 10.1055/s-0031-1281820
Fort- und Weiterbildung

© Georg Thieme Verlag KG Stuttgart · New York

Therapiestandards in der Behandlung des Morbus Parkinson

Current Treatment Strategies for Parkinson’s DiseaseM. Südmeyer1, 2 , L. Wojtecki1, 2 , A. Schnitzler1, 2
  • 1Neurologische Klinik – Bewegungsstörungen und Neuromodulation, Medizinische Fakultät, UKD, Düsseldorf
  • 2Institut für Klinische Neurowissenschaften und Medizinische Psychologie, Medizinische Fakultät, UKD, Düsseldorf
Further Information

Publication History

Publication Date:
09 December 2011 (online)

Lernziele

Der vorliegende Übersichtsartikel beschäftigt sich mit den Therapiestandards in der Behandlung des Morbus Parkinson unter Berücksichtigung der Leitlinien der Deutschen Gesellschaft für Neurologie und aktuellster Studienergebnisse. Ziel der Darstellung ist es, Kenntnisse in den 3 folgenden Bereichen zu vermitteln:

Behandlung motorischer Symptome im Früh- und Spätstadium Indikation für tiefe Hirnstimulation und Medikamentenpumpentherapien Therapie nicht motorischer Symptome

Literatur

  • 1 Oertel W H, Reichmann H. Parkinson-Syndrome: Diagnostik und Therapie. In: Diener H C, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie.. Stuttgart: Thieme; 2008: 82-112
  • 2 Braak H, Del Tredici K. Pathophysiologie des sporadischen Morbus Parkinson.  Fortschr Neurol Psychiat. 2010;  78 (Suppl 1) 2-4
  • 3 Wojtecki L, Südmeyer M, Schnitzler A. Current Treatment of Parkinson’s disease.  Dtsch Arztebl. 2007;  104 2513-2522
  • 4 LeWitt P A. Levodopa for the treatment of Parkinson’s disease.  N Engl J Med. 2008;  359 2468-2476
  • 5 Koller W C, Hutton J T, Tolosa E et al. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study.  Neurology. 1999;  53 1012-1019
  • 6 Stocchi F, Rascol O, Kieburtz K et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease – the STRIDE-PD study.  Ann Neurol. 2010;  68 18-27
  • 7 Parkinson Study Group CALM Cohort Investigators . Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease.  Arch Neurol. 2009;  66 563-570
  • 8 Schade R, Andersohn F, Suissa S et al. Dopamine agonists and the risk of cardiac-valve regurgitation.  N Engl J Med. 2007;  356 29-38
  • 9 Zanettini R, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease.  N Engl J Med. 2007;  356 39-46
  • 10 Onofrj M, Bonanni L, De Angelis M V et al. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies.  Parkinsonism Relat Disord. 2009;  15 (Suppl 4) 85-92
  • 11 Fahn S, Shoulson I, Kieburtz K et al. Levodopa and the progression of Parkinson’s disease.  N Engl J Med. 2004;  351 2498-2508
  • 12 Schulz J B, Gerlach M, Gille G et al. Basic science in Parkinson’s disease: its impact on clinical practice.  J Neurol. 2011;  258 (Suppl 2) 299-306
  • 13 Wallace B A, Ashkan K, Heise C E et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys.  Brain. 2007;  130 2129-2145
  • 14 Rascol O. „Disease-modification“ trials in Parkinson disease: target populations, endpoints and study design.  Neurology. 2009;  72 (Suppl 2) 51-58
  • 15 Olanow C W, Rascol O, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease.  N Engl J Med. 2009;  361 1268-1278
  • 16 Schapira A H, Albrecht S, Barone P et al. Rationale for delayed-start study of pramipexole in Parkinson’s disease: the PROUD study.  Mov Disord. 2010;  25 1627-1632
  • 17 Rascol O, Fitzer-Attas C F, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.  Lancet Neurol. 2011;  10 415-423
  • 18 Kostic V, Przedborski S, Flaster E et al. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease.  Neurology. 1991;  41 202-205
  • 19 Entacaponeto Tolcapone Switch Study Investigators . Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease.  Mov Disord. 2007;  22 14-19
  • 20 Rascol O, Brooks D J, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.  Lancet. 2005;  365 947-954
  • 21 Wolf E, Seppi K, Katzenschlager R et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease.  Mov Disord. 2010;  25 1357-1363
  • 22 Stocchi F, Giorgi L, Hunter B et al. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease.  Mov Disord. 2011;  26 1259-1265
  • 23 Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson’s disease.  N Engl J Med. 2006;  355 896-908
  • 24 Williams A, Gill S, Varma T et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial.  Lancet Neurol. 2010;  9 581-591
  • 25 Follett K A, Weaver F M, Stern M et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease.  N Engl J Med. 2010;  362 2077-2091
  • 26 Fasano A, Romito L M, Daniele A et al. Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants.  Brain. 2010;  133 2664-2676
  • 27 Clarke C E, Worth P, Grosset D et al. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease.  Parkinsonism Relat Disord. 2009;  15 728-741
  • 28 Devos D for the French DUODOPA Study Group . Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease.  Mov Disord. 2009;  24 993-1000
  • 29 De Gaspari D, Siri C, Cilia A L et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.  J Neurol Neurosurg Psychiatry. 2006;  77 450-453
  • 30 Ebersbach G, Ebersbach A, Edler D et al. Comparing exercise in Parkinson’s disease – the Berlin LSVT®BIG study.  Mov Disord. 2010;  25 1902-1908
  • 31 Ramig L O, Sapir S, Countryman S et al. Intensive voice treatment (LSVT) for patients with Parkinson’s disease: a 2 year follow up.  J Neurol Neurosurg Psychiatry. 2001;  71 493-498
  • 32 Menza M, Dobkin R D, Marin H et al. A controlled trial of antidepressants in patients with Parkinson disease and depression.  Neurology. 2009;  72 886-892
  • 33 Timmermann L, Maier F, Eggers C et al. Demenz bei Morbus Parkinson: Sinnvolle Diagnostik und rationale Therapie.  Fortschr Neurol Psychiat. 2010;  78 513-518
  • 34 Weintraub D, Koester J, Potenza M N et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.  Arch Neurol. 2010;  67 589-595

Dr. Martin Südmeyer

Neurologische Klinik – Bewegungsstörungen und Neuromodulation, Medizinische Fakultät, UKD

Moorenstr. 5

40225 Düsseldorf

Email: martin.suedmeyer@uni-duesseldorf.de